Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.

Fiche publication

Date publication

février 2024

Journal

Journal of neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Scherer L, Soudant M, Pittion-Vouyovitch S, Debouverie M, Guillemin F, Epstein J, Mathey G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38421420

Résumé

one of the most important therapeutic goals in relapse-onset multiple sclerosis is to preclude conversion to secondary progression. Our objective was to determine the risk of progression associated with natalizumab treatment in an registry-based cohort of patients and to identify determinant factors.